Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling

The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated by immunomodulatory antibodies specific for immune checkpoints. Among them, the programmed death ligand-1 (PD-L1) is of particular interest as it is expressed not only on T-cells, but also on other i...

Descripción completa

Detalles Bibliográficos
Autores principales: Passariello, Margherita, D’Alise, Anna Morena, Esposito, Annachiara, Vetrei, Cinzia, Froechlich, Guendalina, Scarselli, Elisa, Nicosia, Alfredo, De Lorenzo, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739323/
https://www.ncbi.nlm.nih.gov/pubmed/31511565
http://dx.doi.org/10.1038/s41598-019-49485-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739323/
https://www.ncbi.nlm.nih.gov/pubmed/31511565
http://dx.doi.org/10.1038/s41598-019-49485-3

Ejemplares similares